Oxytocin

Carbetocin (Pabal, Duratocin) is a longer-acting oxytocin analogue used in some countries for the same obstetric indications. Desmopressin and vasopressin are structurally related nonapeptides but act on different receptors and are used for very different things (diabetes insipidus, shock). They are not interchangeable with oxytocin.

The obstetric evidence base is decades deep and consistent: oxytocin shortens labour where contractions are inadequate, and active management of the third stage with oxytocin reduces postpartum blood loss compared with expectant management. The WHO CHAMPION trial (Widmer et al., 2018, NEJM) randomised 29,645 women across 23 countries to oxytocin or heat-stable carbetocin and found both effective at preventing postpartum haemorrhage, with carbetocin non-inferior, a useful real-world benchmark for oxytocin's baseline efficacy. The off-label "social" evidence is a different story. After more than a decade of small, often unreplicated positive studies, two large rigorously designed RCTs delivered negative results: Sikich et al. (2021, NEJM) randomised 290 children and adolescents with autism to intranasal oxytocin or placebo for 24 weeks and found no benefit on social or behavioural outcomes; Yamasue et al. (2022, Brain) used a novel enhanced-bioavailability nasal spray in adults with autism and also found no benefit versus placebo. Walum, Waldman and Young (2016, Biological Psychiatry) is a widely cited statistical critique arguing that much of the published intranasal-oxytocin literature is underpowered and prone to false positives. Cochrane reviewed the autism evidence and concluded it does not currently support oxytocin as a treatment.

For information only, this is a hospital medicine and dosing is set by an obstetric team, not by reading a webpage. Labour induction typically uses a continuous IV infusion of oxytocin in saline, starting in the low milliunits-per-minute range and titrated to uterine activity under continuous fetal heart-rate monitoring. Postpartum haemorrhage prevention and treatment regimens involve a slow IV dose plus an infusion in accordance with WHO and NICE guidance. The intranasal products marketed to consumers for "bonding" or "social warmth" are not approved medicines and are typically sold through research-chemical websites or compounding pharmacies; doses used in published research vary widely (commonly 24–40 IU intranasally) and how much actually reaches the brain at those doses is itself disputed.

In hospital, oxytocin has a well-characterised safety profile but is not a benign drug. Excess uterine stimulation can cause tachysystole, uterine rupture (especially with a scarred uterus) and fetal distress; that is why the infusion is titrated against contractions and fetal monitoring. Oxytocin has a structural similarity to vasopressin and at high cumulative doses with large free-water infusions can cause water retention and hyponatraemia, occasionally severe. Cardiovascular effects (hypotension, tachycardia) are dose-related and more pronounced with rapid IV bolus, so the medicine is given as an infusion. Anaphylaxis is rare. For the unlicensed intranasal "wellness" products, the principal safety problem is not the molecule itself, intranasal oxytocin in trials has generally been well tolerated short-term, but the supply chain: research-chemical and compounded preparations have unverified content, sterility and labelling, and they are not regulated like the hospital drug.